Tesamorelin vs CJC-1295: FDA GHRH vs Research

Tesamorelin is a synthetic GHRH analog composed of 44 amino acids with a trans-3-hexenoic acid modification at the N-terminus. It is the active ingredient in Egrifta SV, manufactured by Theratechnologies and FDA-approved in 2010 for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy.

Its half-life is 26-38 minutes. Daily subcutaneous injection at 2 mg produces a physiological GH pulse that clears within hours. This short half-life means each injection closely mimics the natural GHRH signaling pattern, producing pulsatile GH release without continuous receptor stimulation.

Tesamorelin is the only GHRH analog to have completed Phase III randomized, double-blind, placebo-controlled trials published in top-tier journals. The Falutz 2007 NEJM study and the Stanley 2014 JAMA study represent the gold standard of clinical evidence in this peptide class (Falutz et al., NEJM, 2007). For the complete tesamorelin dosing guide, see our tesamorelin dosage for fat loss article.

CJC-1295 is a synthetic analog of GHRH, specifically a modified version of GRF(1-29), with four amino acid substitutions that protect it from enzymatic degradation. Developed by ConjuChem Biotechnologies (now dissolved), it never progressed past Phase I/II trials. It exists in two formulations with very different pharmacokinetic profiles.

The evidence gap between tesamorelin and CJC-1295 is the single most important factor in this comparison.

Tesamorelin is the only GHRH analog with published data on visceral fat reduction in randomized controlled trials. The results are clinically meaningful: 18% VAT reduction, 69% responder rate, and improvements in hepatic fat content documented by CT scan and MRI.

CJC-1295 has zero published studies measuring visceral fat. Any assumption that it reduces abdominal fat is extrapolated from its GH-elevating properties: elevated GH promotes lipolysis, and elevated IGF-1 shifts nutrient partitioning toward lean tissue. This is physiologically plausible but not clinically proven.

For anyone with visceral fat reduction as their primary documented goal, tesamorelin is the clear evidence-based choice. For the complete tesamorelin dosing protocol, see our tesamorelin dosage for fat loss guide. For a broader comparison of fat-loss peptides, see best peptides for weight loss.

The Stanley 2014 JAMA study documented a benefit beyond VAT reduction: tesamorelin reduced liver fat in subjects with HIV-associated lipodystrophy. This finding has generated research interest in tesamorelin for non-HIV populations with non-alcoholic fatty liver disease (NAFLD).

Triglyceride reduction of approximately 50 mg/dL was documented in the Falutz NEJM study. Adiponectin levels improved in responders, suggesting enhanced insulin sensitivity as a secondary metabolic benefit (Fourman et al., 2012).

CJC-1295 has no liver-specific data. GH elevation generally promotes hepatic lipolysis, but whether CJC-1295 produces clinically meaningful liver fat reduction has not been tested. For patients with NAFLD concerns, tesamorelin has an established published track record.

Tesamorelin requires daily subcutaneous injections at 2 mg. CJC-1295 with DAC offers a significant convenience advantage.

For weekly injection convenience, CJC-1295 with DAC is the clear winner. For evidence-backed daily dosing with a proven metabolic outcome, tesamorelin is the documented standard.

For reconstitution instructions, use our peptide reconstitution calculator. For storage and shelf life, see how long reconstituted peptides last.

Both tesamorelin and CJC-1295 are generally well tolerated, but tesamorelin has far more comprehensive safety data from its Phase III trials.

CJC-1295 with DAC causes more water retention and tingling than tesamorelin because its 6-8-day half-life maintains continuous GH elevation. Tesamorelin's short half-life produces a GH pulse that clears within hours, resulting in less fluid retention. Both compounds share GH-class risks of insulin sensitivity changes and theoretical IGF-1/cancer considerations with long-term use.

For detailed side effect management, see our CJC-1295/ipamorelin side effects guide.

Cost is a significant factor, and the range spans two orders of magnitude depending on the source.

Brand Egrifta SV is prohibitively expensive for most non-HIV patients. Compounded tesamorelin costs roughly the same as compounded CJC-1295. The cost advantage of CJC-1295 no-DAC disappears when adding ipamorelin, which is the standard combination.

For budget-conscious users, the decision between compounded tesamorelin and CJC-1295 with DAC is roughly equivalent in price. The decision then shifts to evidence quality (tesamorelin) versus dosing convenience (CJC-1295 DAC weekly injections).

This comparison has a clear winner on regulatory standing.

Tesamorelin holds FDA approval under NDA 022505, specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. All other use is off-label but legal with a valid prescription. Physicians can legally prescribe tesamorelin off-label for non-HIV patients with visceral adiposity.

CJC-1295 has never been submitted for FDA approval. It is classified as a research chemical. Access is through compounding pharmacies with prescription or research chemical suppliers.

The FDA's 2024 PCAC proceedings may affect compounding availability for both compounds. Users who value regulatory certainty have reason to prefer tesamorelin. For CJC-1295's regulatory context, see our CJC-1295 vs sermorelin comparison.

The decision depends on your primary goal, access to clinical evidence, and practical preferences.

Combining tesamorelin with CJC-1295 is not recommended. Both are GHRH receptor agonists. Stacking two compounds that activate the same receptor provides diminishing returns rather than synergy. The GHRH receptor has a maximum response capacity that does not scale linearly with multiple simultaneous agonists.

Some clinics use tesamorelin blended with ipamorelin (a ghrelin receptor agonist) for GHRH-GHRP synergy. This is pharmacologically sound: two different receptor pathways create a larger GH response than either alone.

Cycling between tesamorelin and CJC-1295 is a strategy some practitioners use. Tesamorelin for an active fat loss phase (3-6 months), then CJC-1295/ipamorelin for maintenance. This leverages tesamorelin's proven VAT reduction during the active window and CJC-1295's weekly convenience during maintenance. For stacking protocols, see our peptide stacking guide.

Tesamorelin is contraindicated in patients with active malignancy, as GH promotion may stimulate tumor growth. It is classified as Category X in pregnancy due to potential fetal harm. Discontinue if malignancy develops during treatment.

CJC-1295 has no FDA-approved labeling and no formal contraindications. Apply the same precautions as any GH-elevating compound: avoid use with active cancer, monitor IGF-1 levels, and check fasting glucose periodically.

Both compounds should be discontinued if IGF-1 exceeds the upper reference range for your age, fasting glucose rises above 126 mg/dL on two consecutive readings, or severe edema develops. Consult a physician before starting either compound. For broader safety context, see our peptide safety guide.